CeriBell, Inc. (CBLL) Spending and interest coverage
- R&D / revenue · 12 months: Value 22.51%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 16.11%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 22.51% | Research and development expense / revenue. Period ending 2026-06-30. $22.95M ÷ $101.96M × 100 ≈ 22.51% |
| Stock-based compensation / revenue · 12 months | 16.11% | Share-based compensation / revenue. Period ending 2026-06-30. $16.43M ÷ $101.96M × 100 ≈ 16.11% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 22.95M USD | Research and Development Expense |
| Revenue | 101.96M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 16.43M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -69.97M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.95M | $101.96M | $16.43M | $-69.97M | (m) | 22.51% | 16.11% | (m) | (m) |
| 2026-03-31 | $21.06M | $95.07M | $13.60M | $-64.94M | (m) | 22.15% | 14.30% | (m) | (m) |
| 2025-12-31 | $19.14M | $89.06M | $12.22M | $-58.40M | (m) | 21.49% | 13.72% | (m) | (m) |
| 2025-09-30 | $17.99M | $82.81M | $11.07M | $-56.69M | (m) | 21.73% | 13.36% | (m) | (m) |
| 2025-06-30 | $16.41M | $77.42M | $9.09M | $-51.98M | (m) | 21.19% | 11.75% | (m) | (m) |
| 2025-03-31 | $14.82M | $71.53M | $7.00M | $-45.46M | (m) | 20.72% | 9.79% | (m) | (m) |
| 2024-12-31 | $13.56M | $65.44M | $5.41M | $-39.71M | (m) | 20.72% | 8.27% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $8.99M | $45.23M | $2.68M | $-30.04M | (m) | 19.89% | 5.92% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |